Tandem Diabetes Care, Inc. has agreed to pay Roche Holding $36 million over a five year period to settle a patent infringement claim.
On May 21, Tandem Diabetes Care and Roche agreed to resolve all actual or potential patent disputes related to Tandem's slim X2 pump and EP Patent No. 2 196 231 B1 and EP Patent No. 1 970 677 B1.
The two companies have granted each other licenses to patents on the insulin delivery systems for the next 10 years.
Tandem will pay an initial payment of $8 million, and the remaining balance will be paid in four equal annual installments thereafter.
Swiss pharmaceutical company Roche filed an action in December 2023 alleging one of Tandem's insulin pumps infringed upon its patent. Roche was seeking monetary damages and for Tandem to stop selling the t:slim X2 pump.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.